Management of Ventricular Arrhythmias Worldwide

A new guideline for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death has been published by the European Society of Cardiology (ESC). Beside the 2017 American Heart Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS) guideline and the 2020 Canadian Cardiovascular Society/ Canadian Heart Rhythm Society (CCS/CHRS) position statement, this guideline provides evidence-based recommendations for clinical practice. As these recommendations are periodically updated integrating the latest scientific evidence, there are similarities in many aspects. Nevertheless, notable differences in the recommendations can be found resulting from different scopes and publication years, differences in data selection, interpretation, and weighing, and regional factors such as differing drug availability. The aim of this paper is to compare specific recommendations to identify differences while acknowledging the commonalities and to provide an overview of the status of current recommendations with a special emphasis on gaps in evidence and future directions of research. Overall, the recent ESC guideline places a greater emphasis on the value of cardiac magnetic resonance, genetic testing in cardiomyopathies and arrhythmia syndromes, and the use of risk calculators for risk stratification. Further significant differences can be found regarding diagnostic criteria for genetic arrhythmia syndromes, the management of hemodynamically well-tolerated ventricular tachycardia, and primary preventive implantable cardioverter-defibrillator therapy. (J Am Coll Cardiol EP 2023;9:715-728) (c) 2023 by the American College of Cardiology Foundation.